Share your thoughts on our News & Insights section. Complete our survey to help us improve.
Derren Nathan

Derren Nathan

Head of Equity Research

Derren leads our Equity Research team with more than 15 years of experience in his field. Derren enjoys exploring the complex pharmaceutical sector and presenting share ideas for retail investors. He focuses on identifying exceptional companies poised for long-term success through outstanding customer propositions, translating into potential market-beating growth or sustainable dividends.

Covers

Share research and insight

Latest content from Derren

November 2024

How to invest in VCTs – plus some of the successes and failures
27th November 2024
Pets at Home: full-year guidance downgraded in subdued market
27th November 2024
Mitchells & Butlers: full year profits recover, trading still robust
27th November 2024
Compass Group: 2024 in line, on course for more growth in 2025
26th November 2024
NVIDIA: Q3 results and Q4 guidance ahead of forecasts
21st November 2024
CVS Group: trading in-line despite soft UK demand
20th November 2024
US smaller companies set for success? – 3 share ideas
20th November 2024
Imperial Brands: full-year results in line, more growth expected
19th November 2024
Next week on the stock market
15th November 2024
Alibaba: Q2 results broadly in line as cash flows come under pressure
15th November 2024
Opportunity among the G20 leaders – 4 share ideas
15th November 2024
AstraZeneca: guidance raised again after Q3 beat
12th November 2024
Trump wins the 2024 US Election – 3 US share ideas
6th November 2024
Novo Nordisk: Q3 numbers mixed, Wegovy growth shines
6th November 2024

October 2024

Haleon: profit growth slows in Q3, full year guidance unchanged
31st October 2024
Shell: $3.5bn buyback after Q3 earnings beat
31st October 2024
Eli Lilly: full year guidance reduced after Q3 miss
31st October 2024
Visa: Q4 estimates just beaten, more growth expected this year
31st October 2024
GSK: full-year guidance confirmed despite weak Q3 vaccine sales
30th October 2024
AMD: another strong quarter but guidance disappoints
30th October 2024
BP: Q3 shareholder payouts on target as debt levels inch up
29th October 2024
Pfizer: Q3 revenue beat, guidance upgraded
29th October 2024
PayPal: Q3 beats but guidance a little soft
29th October 2024
McDonalds: third-quarter profit in-line despite sales disappointment
29th October 2024
Baker Hughes: Q3 sees strong profit growth but orders slip
23rd October 2024
Verizon: full-year guidance unchanged after flat Q3 revenue
22nd October 2024
How to invest for income in the US stock market – 3 share ideas
17th October 2024
Entain: small upgrade after strong Q3
17th October 2024
ASML: beats third-quarter guidance, but outlook disappoints
16th October 2024
Whitbread: management in confident mood despite H1 growth stutter
16th October 2024
China’s biggest stimulus package since COVID-19 – 3 share ideas to benefit
11th October 2024
Five shares to watch 2024 – where are they now?
10th October 2024
GSK: $2.2bn agreement to settle 93% of US Zantac cases
10th October 2024
Imperial Brands: trading in line, higher shareholder payouts targeted
8th October 2024
J D Wetherspoon: dividends back on table after profits bounce back
4th October 2024
4 share ideas for the future of energy
2nd October 2024

August 2024

Alibaba: first quarter results fall shy of estimates
15th August 2024
Admiral Group: Half year profits sail past forecasts
15th August 2024
TUI Group: Full year guidance confirmed after solid Q3
14th August 2024
Aviva: focus on margins drives first half profit growth
14th August 2024
Dowlais: another downgrade as first half sales fall 5%
13th August 2024
Barrick Gold: commodity prices boost Q2 earnings
12th August 2024
Entain: Euros boost first half results, full-year guidance upgraded
8th August 2024
Eli Lilly: revenue and earnings guidance upgraded after strong Q2
8th August 2024
Novo Nordisk: strong Q2 sales growth, profits hit by impairments
7th August 2024
Chevron – misses Q2 estimates as weak refining margins bite
2nd August 2024
Smith & Nephew – guidance unchanged as Q2 growth accelerates
1st August 2024
Haleon - profit outlook raised after solid Q2
1st August 2024
Shell - new buyback after Q2 earnings beat
1st August 2024

July 2024

GSK - another upgrade after strong Q2
31st July 2024
AMD – AI demand drives Q2 earning beat
31st July 2024
Semiconductors, AI and geopolitical tensions – what’s next for investors?
31st July 2024
Mastercard – full year guidance unchanged after earnings beat
31st July 2024
Pfizer – revenue returns to growth in Q2, guidance raised
30th July 2024
PayPal – beats Q2 guidance, full-year outlook improved
30th July 2024
BP – mixed results but strong cashflows underpin more buybacks
30th July 2024
Entain – BetMGM mid-term guidance moves further out
29th July 2024
McDonald's – growth stutters in the second quarter
29th July 2024
Baker Hughes – order growth returns, full-year guidance raised
26th July 2024
AstraZeneca – Strong second quarter supports guidance upgrade
25th July 2024
CVS Group – M&A focus shifts down under, from tough UK market
25th July 2024
Mitchells & Butlers – trading remains in-line, as third quarter growth slows
25th July 2024
British American Tobacco – On track to meet 2024 guidance
25th July 2024
Visa – third quarter in line, payment volumes slow into fourth quarter
24th July 2024
Compass Group - guidance upgrade after strong third quarter
23rd July 2024
ASML - order intake rebounds, 2024 guidance unchanged
17th July 2024
Five shares to watch 2024 – how are they performing so far this year?
11th July 2024
JD Wetherspoon – growth holding steady in final quarter
10th July 2024
Next week on the stock market
5th July 2024
The world’s population is ageing – 3 share ideas which could benefit
4th July 2024

Social handles

@nathan_derren

CV

Head of Equity Research

Hargreaves Lansdown

July 2022 - Present

Head of Research

Hybridian LLP

July 2018 - July 2022 • 4 yrs 1 mo

Investment research

Hybridian LLP

Apr 2014 - July 2022 • 8 yrs 4 mos

In the press

Press articles quoting or featuring our experts and spokespeople. Hargreaves Lansdown is not responsible for these articles’ content and accuracy and may not share the views of the author or publication listed below.

dailymail.co.uk
Chancellor Jeremy Hunt's plan to sell off NatWest shares 'could cost taxpayers £28bn'
morningstar.com
Traders boost bets on mid-2024 rate cut by Bank of England as U.K. jobs market cools
thisismoney.co.uk
Analysts eye more M&A for Britain's hospitality sector